OncLive TV

Omar Nadeem, MD, discusses the uptake of novel therapies in heavily pretreated multiple myeloma.

Adam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.

Leanne Burnham, PhD, discusses health disparities in prostate cancer.

David M. O'Malley, MD, discusses the promise of antibody-drug conjugates in ovarian cancer.

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Eirwen M. Miller, MD, discusses the safety and efficacy of veliparib vs other PARP inhibitors used in the treatment of patients with ovarian cancer.

Scott Tagawa, MD, MS, FACP, discuses the benefits of radium-223 dichloride in prostate cancer.

Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.

Robert Dreicer, MD, discusses the initial findings with sabizabulin in metastatic castration-resistant prostate cancer.

Paolo Ghia, MD, PhD, discusses the clinical implications of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Shaji K. Kumar, MD, discusses the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

Daniel Pollyea, MD, MS, discusses improving induction outcomes for newly diagnosed patients with acute myeloid leukemia.

David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.

Michael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Jeremy C. Jones, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in colorectal cancer.

Bhavana Pothuri, MD, discusses treatment considerations for PARP inhibitors in patients with ovarian cancer.

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

Adam Sperling, MD, PhD, discusses managing CAR T-cell therapy–related toxicities in multiple myeloma.

Scott T. Tagawa, MD, MS, FACP, discusses tumor targeting with radionuclides in prostate cancer.

Lisa A. Carey, MD, FASCO, discusses the clinical implications of the phase 3 FeDeriCa trial in HER2-positive breast cancer.

Renold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.

David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.

Adam Sperling, MD, PhD, discusses future research directions with idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.

Sandy Wong, MD, discusses treatment goals for patients with systemic amyloidosis.

Tycel Jovelle Phillips, MD, discusses the next steps in evaluating the combination of venetoclax, lenalidomide, and rituximab in mantle cell lymphoma.

Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.